TABLE 1.
Peak-to-trough methods of calculation and data source
| DRUG | METHOD OF CALCULATION AND DATA SOURCE |
|---|---|
| LAI medications | |
| Haloperidol decanoate | Derived from the reported dose-normalized Cmax and Cmin19 |
| Olanzapine pamoate | Reported in the literature20 |
| Paliperidone palmitate | Predicted median Cmax and median Cmin in a PK model21 |
| Risperidone LAI | PK model22 |
| Zuclopenthixol decanoate | Reported in the literature14 |
| Oral medications | |
| Haloperidol | Calculated from Cmax and Cmin in the literature19 |
| Olanzapine | Derived from graph depicting steady-state PK23 |
| Paliperidone ER | Calculated from the steady-state mean Cmax and Cmin in a PK study24,25 |
| Risperidone | Calculated from the average peak-to-trough fluctuation of the active moiety derived from a PK study and predicted from a PK model22,24 |
LAI: long-acting injectable; Cmax: maximum plasma concentration; Cmin: minimum plasma concentration; ER: extended release; PK: pharmacokinetics.